Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations.

Li, Pengfei; de Vries, Annemarie C; Kamar, Nassim; Peppelenbosch, Maikel P; Pan, Qiuwei

Li, Pengfei; de Vries, Annemarie C; Kamar, Nassim; Peppelenbosch, Maikel P; Pan, Qiuwei.

Li P; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, NL-3015 Rotterdam, Netherlands.
de Vries AC; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, NL-3015 Rotterdam, Netherlands.
Kamar N; Department of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire Rangueil, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease, Paul Sabatier University, Toulouse, France.
Peppelenbosch MP; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, NL-3015 Rotterdam, Netherlands.
Pan Q; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, NL-3015 Rotterdam, Netherlands. Electronic address: q.pan@erasmusmc.nl.

Lancet Microbe ; 3(5): e325-e326, 2022 05.

Article in English | MEDLINE | ID: covidwho-1740347

Subject(s)

COVID-19; SARS-CoV-2; Antibodies, Viral; Humans; Immunocompromised Host; SARS-CoV-2/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Lancet Microbe Year: 2022 Document Type: Article Affiliation country: S2666-5247(22)00061-1

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google